ArticleAnnals of clinical and translational neurology2024
Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy.
Vanessa L Hull, Yan Wang, Jennifer McDonough, Meina Zhu, Travis Burns, Najmah Al Ramel, Ali Dehghani, Fuzheng Guo, David Pleasure
Open access · goldAbstract read
In one paragraphArticle in Annals of clinical and translational neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors at 2 institutions in 1 country.
Yan WangDepartment of Neurology, UC Davis School of Medicine, Sacramento, California, USA.
Meina ZhuDepartment of Neurology, UC Davis School of Medicine, Sacramento, California, USA.
Travis BurnsDepartment of Neurology, UC Davis School of Medicine, Sacramento, California, USA.
Najmah Al RamelDepartment of Biological Sciences, Kent State University, Kent, Ohio, USA.
Ali DehghaniDepartment of Neurology, UC Davis School of Medicine, Sacramento, California, USA.
Fuzheng GuoDepartment of Neurology, UC Davis School of Medicine, Sacramento, California, USA.
Shriners Hospitals for Children - Erie · USKent State University · US
Funding
UC Davis Clinical and Translational Science CenterUL1TR001860 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KENYON, NICHOLAS J., LYLES, COURTNEY REES · 2016 to 2025
$47.3MUC Davis CTSC TL1 Administrative Supplement to Recognize Excellence in Diversity, Equity, Inclusion, and Accessibility MentorshipTL1TR001861 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MEDICI, VALENTINA · 2016 to 2025
$4.7MThe curious case of PARP1 in CNS myelin formation and repairR01NS123165 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Fuzheng Guo · 2022 to 2026
$2.5MGlial HIFa: mechanisms and implications in hypoxia/ischemia-induced oligodendroglial pathologyR01NS123080 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GUO, FUZHENG · 2021 to 2025
$2.3MSOX2-regulated astrocyte homeostasis and pathophysiologyR01NS134887 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Fuzheng Guo · 2024 to 2026
$1.8MUsing genetic approaches to explore the role of group I PAKs in developmental myelination of the mammalian CNSR21NS125464 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GUO, FUZHENG · 2022 to 2022
$439kManipulating N-acetyl-L-aspartate transport to treat Canavan leukodystrophyR21NS126173 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PLEASURE, DAVID E. · 2022 to 2023
$432kManipulating N-acetyl-L-aspartate to reverse Canavan leukodystrophyR21NS117386 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PLEASURE, DAVID E. · 2020 to 2020
$432kNanoparticle-mediated delivery of a base editor for in utero treatment of Canavan DiseaseR21NS133881 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PLEASURE, DAVID E., WANG, AIJUN · 2023 to 2023
$424kNCATS NIH HHS TL1 TR001861NCATS NIH HHS UL1 TR001860NIH HHS R21NS117386NIH HHS R21NS133881NINDS NIH HHS R01 NS123080NINDS NIH HHS R01 NS123165NINDS NIH HHS R01 NS134887NINDS NIH HHS R21 NS117386NINDS NIH HHS R21 NS125464NINDS NIH HHS R21 NS126173NINDS NIH HHS R21 NS133881
6 · The paper itselfAbstract
Canavan disease is a leukodystrophy caused by ASPA mutations that diminish oligodendroglial aspartoacylase activity, and is characterized by markedly elevated brain concentrations of the aspartoacylase substrate N-acetyl-l-aspartate (NAA) and by astroglial and intramyelinic vacuolation. Astroglia express NaDC3 (encoded by SLC13A3), a sodium-coupled transporter for NAA and other dicarboxylates. Astroglial conditional Slc13a3 deletion in aspartoacylase-deficient Canavan disease model mice ("CD mice") reversed brain NAA elevation and improved motor function. These results demonstrate that astroglial NaDC3 contributes to brain NAA elevation in CD mice, and suggest that suppressing astroglial NaDC3 activity would ameliorate human Canavan disease.
Indexed as
Canavan DiseaseNeurodegenerative DiseasesAnimalsAspartic AcidAstrocytesBrainMiceOligodendrogliaSymportersAspartic AcidSlc13a3 protein, mouseSymporters
Identifiers
PMID38282243
PMCPMC11021635
OpenAlexW4391320538
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390